Granules India Limited has announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company’s Board of Directors approved the standalone and consolidated financial statements, which reflect the company’s performance and strategic initiatives. The results detail revenue from operations, expenses, profits, and other comprehensive income, providing insight into the company’s financial health. Additionally, the report includes details on the incorporation of two new subsidiaries in Brazil and Mexico.
Granules India Reports Q2 FY27 Financial Performance
Granules India Limited has announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The Board of Directors, at their meeting on November 02, 2026, approved the standalone and consolidated financial results prepared under Indian Accounting Standards (Ind-AS).
Standalone Financial Highlights (Q2 FY27)
For the quarter ended September 30, 2026, Granules India reported a total income of ₹9,687.32 million. Total expenses amounted to ₹8,226.79 million, leading to a profit before tax of ₹1,460.53 million. After tax expenses of ₹375.37 million, the profit for the period stood at ₹1,085.16 million. Other comprehensive income contributed positively, resulting in a total comprehensive income of ₹1,260.07 million.
Consolidated Financial Highlights (Q2 FY27)
On a consolidated basis, the Group reported a total income of ₹15,706.59 million for the quarter ended September 30, 2026. Total expenses were ₹13,272.36 million, yielding a profit before tax of ₹2,434.23 million. Following tax expenses of ₹615.86 million, the profit for the period was ₹1,818.37 million. Total comprehensive income for the quarter was ₹2,188.04 million.
Half-Yearly Performance (H1 FY27)
For the half year ended September 30, 2026, standalone revenue from operations reached ₹17,496.98 million. The profit for the period was ₹1,802.62 million. Consolidated revenue from operations for the same period was ₹30,367.48 million, with a profit for the period of ₹3,618.00 million.
Subsidiary Developments
The company has incorporated two wholly owned subsidiaries: Triton Farmaceutica Do Brasil LTDA in Brazil on September 30, 2026, and Triton Farmaceutica, S.A. de C.V. in Mexico on October 22, 2026. These strategic moves are part of the company’s global expansion plans.
Source: BSE
